Ocugen to Host Conference Call on Thursday, November 9 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2023 Financial Results
November 02, 2023 07:30 ET
|
Ocugen
MALVERN, Pa., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
Ocugen Mucosal Vaccine Candidate OCU500 Selected by NIH/NIAID Project NextGen for Inclusion in Clinical Trials
October 10, 2023 06:30 ET
|
Ocugen
NIAID is conducting early phase clinical trials on select next generation vaccine candidates with the intent to identify the most effective platforms and delivery routesOCU500 will be tested as both...
Ocugen to Present at the 2023 Cell & Gene Meeting on the Mesa
October 04, 2023 07:00 ET
|
Ocugen
MALVERN, Pa., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
Ocugen CSO to Participate in 4th Annual Gene Therapy for Ophthalmic Disorders Conference
September 29, 2023 07:30 ET
|
Ocugen
MALVERN, Pa., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
Ocugen to Participate in Fireside Chat at Chardan’s 7th Annual Genetic Medicines Conference
September 27, 2023 19:30 ET
|
Ocugen
MALVERN, Pa., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
Ocugen, Inc. Announces Connie Collingsworth Joins Business Advisory Board
September 21, 2023 07:30 ET
|
Ocugen
MALVERN, Pa., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
Ocugen to Participate in Panel at Cantor Fitzgerald Global Healthcare Conference 2023
September 20, 2023 08:00 ET
|
Ocugen
MALVERN, Pa., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
Ocugen Announces Positive Clinical Study Update from the Phase 1/2 Trial of OCU400, a Modifier Gene Therapy Product Candidate, for the Treatment of Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA)
September 13, 2023 08:15 ET
|
Ocugen
Favorable safety and tolerability profile of OCU400 investigational drug product in RP and LCA subjects to dateClinical study update suggests continued positive trends in Best-Corrected Visual Acuity...
Ocugen to Host Virtual Investor & Analyst Event on September 13, 2023
September 12, 2023 19:30 ET
|
Ocugen
MALVERN, Pa., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
Ocugen Provides Business Update with Second Quarter 2023 Financial Results
August 21, 2023 16:32 ET
|
Ocugen
Conference Call and Webcast Tomorrow at 8:30 a.m. ET • Investigational New Drug (IND) Applications Cleared for Novel Gene Therapies for Geographic Atrophy Secondary to AMD and for Stargardt Disease ...